바이젠셀 주식회사

{
  "address": "서울특별시 금천구",
  "ceo_name": "기평석",
  "certificate": [
    {
      "cert_number": "20170400280",
      "changes": "",
      "disclosure_date": "2017-03-14",
      "first_cert_date": "2017-03-14",
      "no": "1",
      "type": "연구개발유형",
      "valid_period": "2017-03-14 ~ 2019-03-13"
    },
    {
      "cert_number": "20190400700",
      "changes": "",
      "disclosure_date": "2019-04-08",
      "first_cert_date": "2017-03-14",
      "no": "2",
      "type": "연구개발유형",
      "valid_period": "2019-03-14 ~ 2021-03-13"
    },
    {
      "cert_number": "20210414020025",
      "changes": "",
      "disclosure_date": "2021-04-14",
      "first_cert_date": "2017-03-14",
      "no": "3",
      "type": "연구개발유형",
      "valid_period": "2021-03-14 ~ 2024-03-13"
    },
    {
      "cert_number": "20240328020010",
      "changes": "대표자, 소재지",
      "disclosure_date": "2024-03-28",
      "first_cert_date": "2017-03-14",
      "no": "4",
      "type": "연구개발유형",
      "valid_period": "2024-03-14 ~ 2027-03-13"
    }
  ],
  "company_name": "바이젠셀 주식회사",
  "corp_no": "110111-*******",
  "financials": {
    "2022": {
      "capital_stock": 9503030000,
      "cost_of_sales": 0,
      "current_assets": 69878120000,
      "current_liabilities": 8350839000,
      "gross_profit": 0,
      "net_income": -17390844000,
      "net_income_bs": -17390844000,
      "non_current_assets": 29494164000,
      "non_current_liabilities": 1377637000,
      "non_operating_expenses": 470798000,
      "non_operating_income": 1261582000,
      "operating_profit": -18181628000,
      "revenue": 0,
      "sga_expenses": 18181628000,
      "total_assets": 99372284000,
      "total_equity": 89643808000,
      "total_liabilities": 9728476000
    },
    "2023": {
      "capital_stock": 9582870000,
      "cost_of_sales": 0,
      "current_assets": 54437204000,
      "current_liabilities": 8472338000,
      "gross_profit": 0,
      "net_income": -17878754000,
      "net_income_bs": -17878754000,
      "non_current_assets": 26610179000,
      "non_current_liabilities": 1085780000,
      "non_operating_expenses": 507459000,
      "non_operating_income": 2615411000,
      "operating_profit": -19986706000,
      "revenue": 0,
      "sga_expenses": 19986706000,
      "total_assets": 81047383000,
      "total_equity": 71489265000,
      "total_liabilities": 9558118000
    },
    "2024": {
      "capital_stock": 9631870000,
      "cost_of_sales": 267061000,
      "current_assets": 45877157000,
      "current_liabilities": 8001862000,
      "gross_profit": 11885000,
      "net_income": -14058409000,
      "net_income_bs": -14058409000,
      "non_current_assets": 21469310000,
      "non_current_liabilities": 1318752000,
      "non_operating_expenses": 757470000,
      "non_operating_income": 2005524000,
      "operating_profit": -15306463000,
      "revenue": 278946000,
      "sga_expenses": 15318348000,
      "total_assets": 67346467000,
      "total_equity": 58025853000,
      "total_liabilities": 9320614000
    }
  },
  "industry": "합성의약품 및 기타 완제 의약품 제조업",
  "investment": [],
  "main_products": "세포치료제",
  "phone": "02-2127-****",
  "years": [
    2024,
    2023,
    2022
  ]
}